HIGHLIGHTS
- who: Miner Shao from the (UNIVERSITY) have published the Article: Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial, in the Journal: (JOURNAL) of September/30,/2022
SUMMARY
Received: 19 October 2022 Revised: 27 January 2023 Accepted: 8 February 2023 Notably, squamous NSCLC achieve more favorable pathological remissions to neoadjuvant immuno-chemotherapy than nonsquamous NSCLC. In contrast, the NADIM and CheckMate-816 trials show consistent benefits in squamous and non-squamous NSCLC. Gao et_al report that among EGFR-negative patients, squamous NSCLC has superior . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.